Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from ACADIA Pharmaceuticals ( (ACAD) ) is now available.
On May 29, 2025, Acadia Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders, where three Class III directors were elected to the Board of Directors to serve until the 2028 Annual Meeting. Additionally, stockholders approved the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (ACAD) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on ACADIA Pharmaceuticals stock, see the ACAD Stock Forecast page.
Spark’s Take on ACAD Stock
According to Spark, TipRanks’ AI Analyst, ACAD is a Outperform.
ACADIA Pharmaceuticals’ strong financial performance and positive earnings call are key strengths, driving a favorable overall score. Technical indicators show bullish momentum, though caution is advised due to overbought conditions. The company’s valuation is reasonable, and recent corporate events further bolster its strategic position.
To see Spark’s full report on ACAD stock, click here.
More about ACADIA Pharmaceuticals
Average Trading Volume: 2,113,002
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.71B
For an in-depth examination of ACAD stock, go to TipRanks’ Stock Analysis page.